All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Margetuximab,Retifanlimab,Capecitabine
Therapeutic Area: Oncology Product Name: MGAH22
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
MAHOGANY is a Phase 2/3 clinical trial in two modules designed to evaluate margetuximab in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with advanced or metastatic HER2-positive GC/GEJ.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 131I-omburtamab
Therapeutic Area: Oncology Product Name: 131I-8H9
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Y-mAbs has received a Refusal to File letter from the U.S.FDA regarding the Biologics License Application for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma, which was submitted in August 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Umbralisib
Therapeutic Area: Oncology Product Name: TGR-1202
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
Details:
U.S. FDA has accepted the Company’s New Drug Application (NDA) for umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma (MZL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
SM-88 has demonstrated encouraging tumor responses in 15 different cancers across four separate studies with minimal serious grade 3 or higher adverse events .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Margetuximab,Retifanlimab,MGD013
Therapeutic Area: Oncology Product Name: MGAH22
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Lancet Oncology has published results from a Phase 2 study of margetuximab plus pembrolizumab as a chemotherapy-free regimen for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) who have previously been treated with chemotherapy and trastuzumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Omburtamab
Therapeutic Area: Oncology Product Name: 131I-8H9
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
Omburtamab is an investigational, mAb that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types. The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: National Brain Tumor Society
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding June 24, 2020
Details:
This loan aims to support VAL-083’s preparation for participation in the Global Coalition for Adaptive Research’s sponsored trial, Glioblastoma Adaptive Global Innovative Learning Environment study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Oral SM-88 is designed to selectively disrupt cancer’s metabolic process and cause cancer cell death; SM-88 is currently in a pivotal trial for 3rd-line pancreatic cancer. Preclinical data shows statistically significant tumor reduction in SM-88 treated arms versus controls.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: HSBC
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Financing June 08, 2020
Details:
The financing will help ensure the company have the necessary resources to continue achieving its goals to advance the development of NBTXR3.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
